AryoGen Pharmed
Profile managed by Bizz IdDescription
Products
12 productsBrand: Stivant. Bevacizumab biosimilar. Metastatic colorectal cancer, progressive glioblastoma, NSCLC, advanced or metastatic kidney cancer, epithelial ovarian, fallopian tube and primary peritoneal cancer, cervical cancer and metastatic breast cancer.
Finished product (FDF)
Verified on 2026-10-21
Brand: Artenix. Monoclonal IgG2 antibody binding RANKL. Indication not stated on the website.
Finished product (FDF)
Verified on 2026-10-21
Brand: Arylia. Human IgG2 monoclonal antibody binding RANKL. Osteoporosis (the website describes postmenopausal, male and treatment-related osteoporosis).
Finished product (FDF)
Verified on 2026-10-21
Brand: Aryxent. Monoclonal antibody blocking IL-4 and IL-13. Atopic dermatitis, asthma, eosinophilic esophagitis, chronic spontaneous urticaria, prurigo nodularis and COPD. Aryxent 200 and Aryxent 300 presentations.
Finished product (FDF)
Verified on 2026-10-21
Brand: Coageight. Recombinant coagulation factor VIII, Fc fusion protein, produced in CHO cells. Treatment and prevention of bleeding in haemophilia A, all age groups.
Finished product (FDF)
Verified on 2026-10-21
Brand: Altebrel. Etanercept biosimilar, TNF-blocking fusion protein produced in CHO cells. Rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis-related arthritis and plaque psoriasis. Prefilled syringes 25 mg and 50 mg.
Finished product (FDF)
Verified on 2026-10-21
Brand: Rheuflix. Contains infliximab; chronic inflammatory diseases, particularly rheumatoid arthritis.
Finished product (FDF)
Verified on 2026-10-21
Brand: AryoSeven. Glycoprotein produced in BHK cells by recombinant technology. Control, treatment and prevention of bleeding in congenital haemophilia A or B with inhibitors, acquired haemophilia, congenital factor VII deficiency and Glanzmann's thrombasthenia. Marketed as 1.2 mg (60 KIU), 2.4 mg (120 KIU) and 4.8 mg (240 KIU) lyophilised powder for injection.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Zytux. Rituximab biosimilar, chimeric monoclonal antibody produced in CHO cells. Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, GPA and MPA, pemphigus vulgaris. 100 mg and 500 mg vials for infusion.
Finished product (FDF)
Verified on 2026-10-21
Brand: Temziva. Contains tocilizumab (IL-6 blocker). Cytokine release syndrome (CRS) in adults and children aged 2 and older with confirmed COVID-19. 400 mg/20 mL vial.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: AryoTrust. Trastuzumab biosimilar produced in recombinant CHO cells. HER2-overexpressing early and metastatic breast cancer and metastatic gastric cancer. Lyophilised powder for infusion, 150 mg and 440 mg.
Finished product (FDF)
Verified on 2026-10-21
Brand: VedAryo. Humanized IgG1 monoclonal antibody binding integrin α4β7, produced in CHO cells.
Finished product (FDF)
Verified on 2026-10-21